Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway

Cardiovascular Therapeutics

Volumn 32, Issue 6, 2014, Pages 276-282

  Xie, Wenchao ^a   Li, Ping ^a   Wang, Zhengdong ^a   Chen, Jian ^a   Lin, Zhihai ^a   Liang, Xiangwen ^a   Mo, Yingxi ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndromes; MiR 155 SHIP 1; Percutaneous coronary intervention; Rosuvastatin

Indexed keywords

CYTOKINE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; MICRORNA; MIRN155 MICRORNA, HUMAN; PHOSPHATASE; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ACUTE CORONARY SYNDROME; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR DISEASES; CYTOKINES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICRORNAS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHORIC MONOESTER HYDROLASES; PROSPECTIVE STUDIES; PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY;

EID: 84911394037     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12098     Document Type: Article

References (36)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
2. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101:2883-2888.
3. Sun W, Zheng L, Huang L. Role of unusual CD4+ CD28- T cells in acute coronary syndrome. Mol Biol Rep 2012;39:3337-3342.
4. Giubilato S, Liuzzo G, Brugaletta S, et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: Exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 2011;32:1214-1226.
5. Soejima H, Irie A, Miyamoto S, et al. Preference toward a T-helper type 1 response in patients with coronary spastic angina. Circulation 2003;107:2196-2200.
6. Ke D, Fang J, Fan L, et al. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coron Artery Dis 2013;24:334-341.
7. Link A, Ayadhi T, Bohm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006;27:2945-2955.
8. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
9. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-619.
10. Huang RS, Hu GQ, Lin B, et al. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Investig Med 2010;58:961-967.
11. Kurowska-Stolarska M, Alivernini S, Ballantine LE, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 2011;108:11193-11198.
12. Zhou Q, Haupt S, Kreuzer JT, et al. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis 2014, doi: 10.1136/annrheumdis-2013-204377. [Epub ahead of print].
13. Stahl HF, Fauti T, Ullrich N, et al. miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated suppression. PLoS One 2009;4:e7158.
14. Escobar TM, Kanellopoulou C, Kugler DG, et al. miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity 2014;40:865-879.
15. Kohlhaas S, Garden OA, Scudamore C, et al. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009;182:2578-2582.
16. Yun KH, Oh SK, Rhee SJ, et al. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2011;146:68-72.
17. Takano H, Ohba T, Yamamoto E, et al. Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention. Am J Cardiol 2013;111:1688-1693.
18. Liu B, Tonkonogy SL, Sartor RB. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology 2011;141:653-662, 662.e1-662.e4.
19. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-2035.
20. Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23:869-876.
21. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-1411.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
23. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
25. Elsabrouty R, Jo Y, Dinh TT, et al. Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from membranes of permeabilized cells. Mol Biol Cell 2013;24:3300-3308.
26. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
27. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
28. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692.
29. Wang Z, Dai H, Xing M, et al. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes. J Cardiovasc Pharmacol Ther 2013;18:327-333.
30. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-III43.
31. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-1534.
32. Banerjee A, Schambach F, DeJong CS, et al. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol 2010;40:225-231.
33. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009;30:80-91.
34. Tarasenko T, Kole HK, Chi AW, et al. T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci USA 2007;104:11382-11387.
35. Titov DV, Gilman B, He QL, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011;7:182-188.
36. Locke NR, Patterson SJ, Hamilton MJ, et al. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 2009;183:975-983.